Background
Background The efficacies of second-
The efficacies of secondgeneration antipsychotic medications in generation antipsychotic medications in reducing symptoms are reasonably well-reducing symptoms are reasonably welldocumented, buttheir effects on cognition documented, buttheir effects on cognition are less clearly understood. are less clearly understood.
Aims Aims To undertake an interim analysis
To undertake an interim analysis of an open label, 2-year study examining of an open label, 2-year study examining the effects of quetiapine on cognition in the effects of quetiapine on cognition in patients with a first episode of patients with a first episode of schizophrenia and related disorders. schizophrenia and related disorders.
Method Method Cognitive testing was
Cognitive testing was performed before quetiapine wasinitiated performed before quetiapine wasinitiated and repeated after 3, 6 and12 months of and repeated after 3, 6 and12 months of treatment.To date,13 patients have been treatment.To date,13 patients have been fully assessed (mean dose 517.9 mg/day; fully assessed (mean dose 517.9 mg/day; s.d. s.d.¼225.8). 225.8).
Results

Results Statistically significant
Statistically significant improvement was noted on measures of improvement was noted on measures of attention (Continuous PerformanceTest; attention (Continuous PerformanceTest; CPT), verbal productivity (Verbal Fluency CPT), verbal productivity (Verbal Fluency Test) and executive function (Object Test) and executive function (Object AlternationTest) after 6 and12 months of AlternationTest) after 6 and12 months of treatment.For the CPT, improvement treatment.For the CPT, improvement wasalsonotedafter 3 monthsoftreatment. wasalsonotedafter 3 monthsoftreatment.
Conclusions Conclusions During treatment for
During treatment for 1year with quetiapine, cognitive 1year with quetiapine, cognitive performance was improved in young performance was improved in young patients with psychosis.Continued patients with psychosis.Continued controlled investigations of the effects of controlled investigations of the effects of quetiapine on cognition are desirable. quetiapine on cognition are desirable.
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This study describes an interim analysis of This study describes an interim analysis of changes in cognitive function in young changes in cognitive function in young patients with a first episode of psychosis patients with a first episode of psychosis during treatment with quetiapine. The during treatment with quetiapine. The symptomatic relief afforded by second-symptomatic relief afforded by secondgeneration antipsychotic medications generation antipsychotic medications (clozapine, risperidone, olanzapine and (clozapine, risperidone, olanzapine and quetiapine) is well-described (Kane quetiapine) is well-described (Kane et al et al, , 1988; Marder & Meibach, 1994) . The sec-1988; Marder & Meibach, 1994) . The second generation agents reduce the positive ond generation agents reduce the positive symptoms but in contrast to the older (typi-symptoms but in contrast to the older (typical) antipsychotics also improve negative or cal) antipsychotics also improve negative or deficit symptoms (Kane deficit symptoms (Kane et al et al, 1988; Hagger , 1988; Hagger et al et al, 1993) . As well, a distinctive side-effect , 1993) . As well, a distinctive side-effect profile, including fewer extrapyramidal profile, including fewer extrapyramidal side-effects, is a defining feature of these side-effects, is a defining feature of these newer agents (Kopala newer agents (Kopala et al et al, 1997) . , 1997). Although the efficacies of second-Although the efficacies of secondgeneration antipsychotics in reducing generation antipsychotics in reducing symptoms are reasonably well-documented, symptoms are reasonably well-documented, their effects on cognition are less clearly their effects on cognition are less clearly understood. Evidence to date, however, understood. Evidence to date, however, indicates that these newer compounds are indicates that these newer compounds are able to target and improve specific aspects able to target and improve specific aspects of cognition (Hagger of cognition (Hagger et al et al, 1993; Hoff , 1993; Hoff et et al al, 1996; Purdon , 1996; Purdon et al et al, 2000) . Specifically, , 2000) . Specifically, treatment with clozapine has been linked treatment with clozapine has been linked to possible improvements in verbal fluency to possible improvements in verbal fluency and visuomotor tracking (Hagger and visuomotor tracking (Hagger et al et al, , 1993; Lee 1993; Lee et al et al, 1994; Hoff , 1994; Hoff et al et al, 1996 Hoff et al et al, ), , 1996 , whereas risperidone treatment has been whereas risperidone treatment has been associated with probable enhancement of associated with probable enhancement of verbal working memory, new learning and verbal working memory, new learning and attention (Green attention (Green et al et al, 1997; Purdon , 1997; Purdon et al et al, , 2000) . A more controversial profile of 2000). A more controversial profile of improvements (which requires replication) improvements (which requires replication) has been demonstrated with olanzapine has been demonstrated with olanzapine treatment (learning, motor skills, executive treatment (learning, motor skills, executive abilities and visuospatial functioning; abilities and visuospatial functioning; Purdon Purdon et al et al, 2000) . A recent meta-analysis , 2000). A recent meta-analysis of the extant literature examining the of the extant literature examining the effects of these medications on cognition effects of these medications on cognition indicated a modest effect size (Keefe indicated a modest effect size (Keefe et al et al, , 1999) . However, in many reports, 1999). However, in many reports, potentially confounding variables were not potentially confounding variables were not ruled out. Difficulties ascertaining drug-ruled out. Difficulties ascertaining drugspecific effects persist (Harvey & Keefe, specific effects persist (Harvey & Keefe, 2001 ). 2001 .
The effects of antipsychotic medication The effects of antipsychotic medication on cognitive function depend on accurate on cognitive function depend on accurate characterisation of the nature and characterisation of the nature and magnitude of cognitive impairment in the magnitude of cognitive impairment in the group of patients to be studied. When group of patients to be studied. When examined longitudinally, patients who are examined longitudinally, patients who are in the early phases of a psychotic disorder in the early phases of a psychotic disorder (first-episode) demonstrate a remarkably (first-episode) demonstrate a remarkably consistent pattern of neuropsychological consistent pattern of neuropsychological deficits over time, at least in the short-term deficits over time, at least in the short-term (Censits (Censits et al et al, 1997) . Longer-term follow-, 1997). Longer-term followup studies are required to determine if up studies are required to determine if further deterioration occurs with illness further deterioration occurs with illness chronicity. In general, patients with non-chronicity. In general, patients with nonaffective psychotic disorders, such as affective psychotic disorders, such as schizophrenia, schizophreniform disorder schizophrenia, schizophreniform disorder and schizoaffective disorder are impaired and schizoaffective disorder are impaired on measures of memory, both verbal and on measures of memory, both verbal and non-verbal, attention, executive function, non-verbal, attention, executive function, fluency and motor speed (Saykin fluency and motor speed (Saykin et al et al, , 1994 (Saykin et al et al, , ). 1994 .
Few studies have examined changes in Few studies have examined changes in cognitive functioning after treatment with cognitive functioning after treatment with quetiapine (Sax quetiapine (Sax et al et al, 1998; Velligan & , 1998; Velligan & Miller, 1999; Purdon Miller, 1999; Purdon et al et al, 2001) . To date, , 2001) . To date, no study has examined patients with a no study has examined patients with a first-episode of psychosis before and after first-episode of psychosis before and after treatment with quetiapine. Despite the treatment with quetiapine. Despite the small number of chronically ill patients small number of chronically ill patients investigated, two double-blind studies investigated, two double-blind studies provided complementary results, demon-provided complementary results, demonstrating significant improvements in verbal strating significant improvements in verbal reasoning, fluency, executive function, reasoning, fluency, executive function, motor speed and verbal memory (Velligan motor speed and verbal memory (Velligan & Miller, 1999; Purdon & Miller, 1999; Purdon et al et al, 2000) . These , 2000). These effects are in contrast to those observed in effects are in contrast to those observed in haloperidol-treated patients (Velligan & haloperidol-treated patients (Velligan & Miller, 1999; Purdon Miller, 1999; Purdon et al et al, 2001) . A , 2001) . A further study documented amelioration of further study documented amelioration of attentional capacity after treatment with attentional capacity after treatment with quetiapine (Sax quetiapine (Sax et al et al, 1998) . , 1998). Cognitive performance is believed to Cognitive performance is believed to be the single most important factor be the single most important factor contributing to longer-term functional contributing to longer-term functional recovery (Green recovery (Green et al et al, 2000) . Consequently, , 2000) . Consequently, the effects of second-generation medi-the effects of second-generation medications on cognition hold exciting promise cations on cognition hold exciting promise for improving functional adaptability, for improving functional adaptability, particularly for those in the early stages of particularly for those in the early stages of illness. The goal of this study was to exam-illness. The goal of this study was to examine first-episode patients and document the ine first-episode patients and document the effects of quetiapine on their cognitive effects of quetiapine on their cognitive abilities. We hypothesised that improve-abilities. We hypothesised that improvements would be noted on measures of ments would be noted on measures of verbal and visuospatial memory, attention verbal and visuospatial memory, attention and executive functioning. ( 2 0 0 2 ) , 1 8 1 ( s u p p l . 4 3 ) , s 4 5^s 4 9 Improvement in cognitive functioning in patients Improvement in cognitive functioning in patients with first-episode psychosis during treatment with first-episode psychosis during treatment with quetiapine: an interim analysis* with quetiapine: an interim analysis* low potential for extrapyramidal side-low potential for extrapyramidal sideeffects, no changes in motor/sensory effects, no changes in motor/sensory performance were anticipated. performance were anticipated.
METHOD METHOD
Subjects Subjects
Preliminary analysis from an ongoing, Preliminary analysis from an ongoing, investigator initiated, 2-year, open label investigator initiated, 2-year, open label study of first-episode patients with a non-study of first-episode patients with a nonaffective psychosis (schizophrenia, schizo-affective psychosis (schizophrenia, schizoaffective disorder, schizophreniform dis-affective disorder, schizophreniform disorder or psychosis not otherwise specified order or psychosis not otherwise specified (NOS)) has been completed. In-or out-(NOS)) has been completed. In-or outpatients were recruited from the Nova patients were recruited from the Nova Scotia Early Psychosis Programme Scotia
Early Psychosis Programme (Halifax, Nova Scotia, Canada) who were (Halifax, Nova Scotia, Canada) who were between the ages of 18 and 65 years. All between the ages of 18 and 65 years. All patients were in the early stages of illness patients were in the early stages of illness and had no more than 25 weeks of cumu-and had no more than 25 weeks of cumulative (lifetime) exposure to antipsychotic lative (lifetime) exposure to antipsychotic medications. Patients were excluded if they medications. Patients were excluded if they had previously been involved in a clinical had previously been involved in a clinical investigation of quetiapine, or had partici-investigation of quetiapine, or had participated in any pated in any clinical trial within the past clinical trial within the past month. No patients were enrolled who month. No patients were enrolled who had a history of serious medical illness. had a history of serious medical illness. All provided written, informed consent All provided written, informed consent before participating in the study. before participating in the study.
Study design Study design
Before initiation of quetiapine, baseline Before initiation of quetiapine, baseline assessments were performed. These assessments were performed. These included the Positive and Negative Syn-included the Positive and Negative Syndrome Scale (PANSS; Kay drome Scale (PANSS; Kay et al et al, 1987) and , 1987) and Global Assessment of Function (GAF; Global Assessment of Function (GAF; DSM-IV; American Psychiatric Associ-DSM-IV; American Psychiatric Association, 1994). These ratings were repeated ation, 1994). These ratings were repeated weekly for 6 weeks, followed by weekly for 6 weeks, followed by monthly monthly thereafter, until study completion.
thereafter, until study completion. Diagnosis was re-evaluated at 6 months. Diagnosis was re-evaluated at 6 months.
For all patients, exposure to anti-For all patients, exposure to antipsychotic medications was brief, so a medi-psychotic medications was brief, so a medication wash-out period was not deemed cation wash-out period was not deemed necessary. Antipsychotic medications were necessary. Antipsychotic medications were crossed over. Quetiapine was initiated at crossed over. Quetiapine was initiated at 25 mg daily, then 25 mg twice daily and 25 mg daily, then 25 mg twice daily and increased by 50-100 mg approximately increased by 50-100 mg approximately every 3 days thereafter until therapeutic every 3 days thereafter until therapeutic dose was reached. The maximum dose dose was reached. The maximum dose employed was 800 mg. (Maximum doses employed was 800 mg. (Maximum doses vary among different countries. According vary among different countries. According to Canadian Guidelines (the country in to Canadian Guidelines (the country in which this study was completed), 800 mg which this study was completed), 800 mg is the maximum recommended dose.) is the maximum recommended dose.) Therapeutic dose was defined as the level Therapeutic dose was defined as the level at which psychotic symptoms were at which psychotic symptoms were adequately controlled in the absence of adequately controlled in the absence of problematic side-effects. problematic side-effects.
Cognitive testing was performed before Cognitive testing was performed before quetiapine was initiated and was repeated quetiapine was initiated and was repeated at 3 months, 6 months and 1 year. The at 3 months, 6 months and 1 year. The neuropsychological test battery was chosen neuropsychological test battery was chosen to assess cognitive domains that are to assess cognitive domains that are impaired in patients with psychotic dis-impaired in patients with psychotic disorders and would have functional signifi-orders and would have functional significance if performance were ameliorated. cance if performance were ameliorated. The battery included the following tasks The battery included the following tasks (for more information see Lezak, 1995) . (for more information see Lezak, 1995) .
(a) (a) Rey Auditory Verbal Learning Test.
Rey Auditory Verbal Learning Test. This task is thought to measure This task is thought to measure immediate memory span, learning immediate memory span, learning curves and strategies for verbally curves and strategies for verbally presented material. presented material.
(b) (b) Benton Visual Retention Test. This task Benton Visual Retention Test. This task is used to measure recall of visually is used to measure recall of visually presented material. presented material.
(c) (c) Wisconsin Card Sorting Test. This task Wisconsin Card Sorting Test. This task has been extensively used in research in has been extensively used in research in schizophrenia and appears to examine schizophrenia and appears to examine abstract behaviour and set-shifting abstract behaviour and set-shifting ability. ability.
(d) (d) Continuous Performance Test. This Continuous Performance Test. This task is thought to measure the capacity task is thought to measure the capacity to sustain a focus of attention. to sustain a focus of attention.
(e) (e) Object Alternation. This is a task that Object Alternation. This is a task that has been borrowed from the non-has been borrowed from the nonhuman primate literature and modified human primate literature and modified to examine executive functioning, to examine executive functioning, specifically response switching. specifically response switching.
(f) (f) Verbal Fluency. This task assesses Verbal Fluency. This task assesses verbal productivity by asking the verbal productivity by asking the subject to spontaneously generate subject to spontaneously generate words that begin with a given letter of words that begin with a given letter of the alphabet. the alphabet.
(g) (g) The Trail Making Test. This is a two-The Trail Making Test. This is a twopart test of visuomotor and conceptual part test of visuomotor and conceptual tracking. tracking.
(h) (h) Grooved Pegboard. This task assesses Grooved Pegboard. This task assesses motor speed and accuracy. motor speed and accuracy.
(i) (i) Finger Tapping. This task measures Finger Tapping. This task measures motor speed. motor speed.
The list of specific variables examined from The list of specific variables examined from each neuropsychological test can be found each neuropsychological test can be found in Table 1 . Alternate versions were in Table 1 . Alternate versions were employed for those tests for which they employed for those tests for which they are available. are available.
Statistics Statistics
Repeated-measures analysis of variance Repeated-measures analysis of variance were performed on selected cognitive test were performed on selected cognitive test scores to examine the effects of quetiapine scores to examine the effects of quetiapine on cognition. The specific cognitive vari-on cognition. The specific cognitive variables were selected to allow comparison ables were selected to allow comparison with studies of the effects of quetiapine on with studies of the effects of quetiapine on cognitive function in patients with chronic cognitive function in patients with chronic psychotic illness. These test variables were psychotic illness. These test variables were thought to be those that are sensitive to: cog-thought to be those that are sensitive to: cognitive difficulties of patients with psychotic nitive difficulties of patients with psychotic disorder, and changes with treatment. disorder, and changes with treatment.
RESULTS RESULTS
A total of 34 patients were enrolled into the A total of 34 patients were enrolled into the study (6 females and 28 males). The sample study (6 females and 28 males). The sample at study entry was 24.1 (s.d. at study entry was 24.1 (s.d.¼6.5) years of 6.5) years of age and had been educated, on average, age and had been educated, on average, for 12.4 (s.d. for 12.4 (s.d.¼2.3) years. At study entry, 2.3) years. At study entry, patients were mildly to moderately ill patients were mildly to moderately ill according to the positive and negative sub-according to the positive and negative subscales of the PANSS. Symptomatic scales of the PANSS. Symptomatic improvement in the positive and negative improvement in the positive and negative sub-scales was noted over time (see Fig. 1 ). sub-scales was noted over time (see Fig. 1 ). At the time of interim analysis, 27 had com-At the time of interim analysis, 27 had completed the 3-month evaluation, 23 finished pleted the 3-month evaluation, 23 finished the 6-month assessment and 13 had reached the 6-month assessment and 13 had reached the 1-year mark. Eight patients' data were the 1-year mark. Eight patients' data were excluded from the study. Three patients excluded from the study. Three patients withdrew because of lack of compliance, withdrew because of lack of compliance, three withdrew consent and two were three withdrew consent and two were discontinued for lack of efficacy. discontinued for lack of efficacy. s 4 6 s 4 6 Twelve patients (35%) were anti-Twelve patients (35%) were antipsychotic medication naıve at the time of psychotic medication naïve at the time of study entry. The remainder had been medi-study entry. The remainder had been medicated for 7.4 (s.d. cated for 7.4 (s.d.¼6.2) weeks on average 6.2) weeks on average as follows: risperidone ( as follows: risperidone (n n¼11); quetiapine 11); quetiapine ( (n n¼6); haloperidol ( 6); haloperidol (n n¼2); loxapine ( 2); loxapine (n n¼2); 2); or olanzapine ( or olanzapine (n n¼1). Mean chlorpromazine 1). d d' ' total score, i.e. the ability to dis-total score, i.e. the ability to discriminate target from non-target items), criminate target from non-target items), Object Alternation (number of persevera-Object Alternation (number of perseverative errors) and Verbal Fluency Test (total tive errors) and Verbal Fluency Test (total score). Simple contrast score). Simple contrast post hoc post hoc tests indi-tests indicated that CPT performance was improved cated that CPT performance was improved at all three time points examined (3-month, at all three time points examined (3-month, 6-month and 1-year) relative to baseline, 6-month and 1-year) relative to baseline, whereas Object Alternation and Verbal whereas Object Alternation and Verbal Fluency capacity was enhanced at 6 months Fluency capacity was enhanced at 6 months and 1 year. and 1 year.
DISCUSSION DISCUSSION
This study documents the interim analysis This study documents the interim analysis of a longer-term study of the effects on of a longer-term study of the effects on cognitive performance in a cohort of young cognitive performance in a cohort of young patients with a first episode of schizo-patients with a first episode of schizophrenia and related disorders who were phrenia and related disorders who were treated with quetiapine. To our knowledge, treated with quetiapine. To our knowledge, the data provide the first clear indication the data provide the first clear indication that cognitive test performance is improved that cognitive test performance is improved in young patients with psychosis who were in young patients with psychosis who were treated with quetiapine. Statistically signifi-treated with quetiapine. Statistically significant improvements were observed on cant improvements were observed on measures of attention, executive function measures of attention, executive function and verbal fluency at 6 months and 1 year and verbal fluency at 6 months and 1 year of treatment. Improvements in attention of treatment. Improvements in attention (CPT) were also noted at the 3-month test-(CPT) were also noted at the 3-month testing session. These findings are consistent ing session. These findings are consistent with studies of chronically ill, medicated with studies of chronically ill, medicated patients. patients.
Memory and attention deficits are Memory and attention deficits are common in patients with psychotic dis-common in patients with psychotic disorders (Lussier & Stip, 2001) , 1994) . Our data clearly demonstrated impairment in these cognitive demonstrated impairment in these cognitive domains at baseline as compared with pub-domains at baseline as compared with published normative data. Of these domains, lished normative data. Of these domains, performance on a measure of attention at-performance on a measure of attention attained normal levels and also underwent tained normal levels and also underwent statistically significant improvement. statistically significant improvement. Performance on verbal and non-Performance on verbal and nonverbal memory measures did not reach verbal memory measures did not reach significance, although there did appear to significance, although there did appear to be an indication of improved functioning be an indication of improved functioning over time. over time. The number of perseverative errors The number of perseverative errors on Object Alternation (a task used to assess on Object Alternation (a task used to assess response switching) was reduced to below response switching) was reduced to below baseline levels for a sample of healthy baseline levels for a sample of healthy controls (details available from author on controls (details available from author on request). In contrast, the number of perse-request). In contrast, the number of perseverative errors from the Wisconsin Card verative errors from the Wisconsin Card Sorting Test did not reliably decrease. Sorting Test did not reliably decrease. However, an unusual However, an unusual pattern of perfor-pattern of performance was observed on this measure: mance was observed on this measure: better scores were observed at baseline better scores were observed at baseline than on subsequent sessions, suggesting a than on subsequent sessions, suggesting a non-representative estimate of baseline non-representative estimate of baseline functioning. A larger sample could permit functioning. A larger sample could permit better understanding of this finding. better understanding of this finding.
There are several advantages to the There are several advantages to the study design employed. The open label study design employed. The open label design ensured that patients were treated design ensured that patients were treated optimally and thus, potential symptomatic optimally and thus, potential symptomatic confounds were minimised. Also, examin-confounds were minimised. Also, examining patients with a first episode of illness ing patients with a first episode of illness is beneficial as the pre-drug status was is beneficial as the pre-drug status was known (naıve or short-term prior exposure) known (naïve or short-term prior exposure) and is likely to contribute minimally to the and is likely to contribute minimally to the observed effects. Finally, the frequency of observed effects. Finally, the frequency of cognitive assessments and adequacy of the cognitive assessments and adequacy of the neuropsychological test battery allowed neuropsychological test battery allowed for the examination of early and longer-for the examination of early and longerterm effects on cognition (Keefe term effects on cognition (Keefe et al et al, , 1999) . At the same time, we were able 1999). At the same time, we were able to diminish the motivational challenges to diminish the motivational challenges that occur with too frequent or elaborate that occur with too frequent or elaborate assessments. assessments.
The lack of a control group (or a group The lack of a control group (or a group of patients treated with another agent) of patients treated with another agent) leaves unanswered whether the improve-leaves unanswered whether the improvements noted were simply a result of facilita-ments noted were simply a result of facilitation because of repeated exposure to the tion because of repeated exposure to the tasks. Several factors argue against this tasks. Several factors argue against this interpretation. First, alternate forms were interpretation. First, alternate forms were employed for those tasks for which they employed for those tasks for which they were available (see Table 1 ). Although this were available (see Table 1 ). Although this measure would not mitigate procedural measure would not mitigate procedural practice effects, content-specific memory practice effects, content-specific memory would not be affected. The greatest influ-would not be affected. The greatest influence of practice may reasonably be ex-ence of practice may reasonably be expected to occur on initial readministration pected to occur on initial readministration with inter-test intervals of 3 months or less. with inter-test intervals of 3 months or less. Performance in our sample continued to Performance in our sample continued to improve beyond the second testing improve beyond the second testing session. Second, patients who are treated session. Second, patients who are treated with conventional antipsychotic medi-with conventional antipsychotic medications do not demonstrate cognitive cations do not demonstrate cognitive improvement with repeated administration improvement with repeated administration of neuropsychological tests (Kern of neuropsychological tests (Kern et al et al, , 1998; Purdon 1998; Purdon et al et al, 2000) . Nevertheless, , 2000) . Nevertheless, without a comparator group, the effects of without a comparator group, the effects of practice cannot be ruled out. Regardless practice cannot be ruled out. Regardless of the basis for improvement, patients in of the basis for improvement, patients in the current study did improve over time the current study did improve over time and this observation may be the most and this observation may be the most meaningful. meaningful.
Despite modest sample size, statistical Despite modest sample size, statistical improvement over time was observed in a improvement over time was observed in a quarter of the cognitive test variables quarter of the cognitive test variables studied. For all other test variables (with studied. For all other test variables (with the exception of the timed motor/sensory the exception of the timed motor/sensory tasks, which were predicted to be tasks, which were predicted to be unchanged), all mean scores showed trends unchanged), all mean scores showed trends towards better performance with treat-towards better performance with treatment. These values supported our hypo-ment. These values supported our hypotheses and will be carefully examined in theses and will be carefully examined in future analyses. future analyses.
The results of this preliminary study are The results of this preliminary study are encouraging but remain tentative. Clearly, encouraging but remain tentative. Clearly, larger sample sizes, along with more rigor-larger sample sizes, along with more rigorous study designs (including patients ous study designs (including patients treated with other antipsychotic medi-treated with other antipsychotic medications) will allow for better character-cations) will allow for better characterisation of the drug-specific effects of isation of the drug-specific effects of quetiapine on various domains of cogni-quetiapine on various domains of cognition. Nevertheless, this study indicates that, tion. Nevertheless, this study indicates that, at least, quetiapine is not likely to have at least, quetiapine is not likely to have adverse effects on cognitive function and adverse effects on cognitive function and could well have beneficial effects. Given could well have beneficial effects. Given the strong relationship between cognition the strong relationship between cognition and functional adaptation, continued inten-and functional adaptation, continued intensive study of the effects of quetiapine on sive study of the effects of quetiapine on cognition is highly desirable. Further data cognition is highly desirable. Further data on patients' functional adaptability after on patients' functional adaptability after treatment with quetiapine and other aspects treatment with quetiapine and other aspects of the study will be forthcoming. of the study will be forthcoming. Censits, D., Ragland, J., Gur, R., Censits, D., Ragland, J., Gur, R., et al et al (1997) & & For the CPT, improvement was also noted after 3 months of treatment.
For the CPT, improvement was also noted after 3 months of treatment.
& & Positive and negative symptoms, as measured by the Positive and Negative Positive and negative symptoms, as measured by the Positive and Negative Syndrome Scale, appear to be well-managed by the doses of quetiapine used in this Syndrome Scale, appear to be well-managed by the doses of quetiapine used in this study. study.
LIMITATIONS LIMITATIONS
& & Without a control group, the effects of practice cannot be ruled out.
Without a control group, the effects of practice cannot be ruled out.
& & Larger sample sizes are required to confirm the validity of these findings. Larger sample sizes are required to confirm the validity of these findings.
& & Further study is required to determine whether these putative improvements in Further study is required to determine whether these putative improvements in cognition translate into enhanced functional adaptability (outcome). cognition translate into enhanced functional adaptability (outcome). 
